@DrChoueiri 1st up w #LITESPARK012 - Len/bel/pembro vs Len/quavonlimab/pembro vs Len/pembro for #kidneycancer. No diff in PFS or OS - likely from strong control cohort. Still no triplet for 1st line metastatic RCC.
@oncoalert #ESMO26 @myESMO

Starting day 3 @myesmo #ESMO26 w kidney/bladder orals! What a great lineup of trials & speakers — #LITESPARK012 w @DrChoueiri, #LITESPARK011 w @DrDanielHeng, #PEPE w @Iacovelli, phase 1 of XmAb819 w @montypal & AK112 ivonescimab w #JunGuo
@oncoalert